Literature DB >> 17020940

Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity.

Carlos Ros1, Marco Gerber, Christoph Kempf.   

Abstract

The unique region of the capsid protein VP1 (VP1u) of human parvovirus B19 (B19) elicits a dominant immune response and has a phospholipase A(2) (PLA(2)) activity, which is necessary for the infection. In contrast to the rest of the parvoviruses, the VP1u of B19 is thought to occupy an external position in the virion, making this region a promising candidate for vaccine development. By using a monoclonal antibody against the most-N-terminal portion of VP1u, we revealed that this region rich in neutralizing epitopes is not accessible in native capsids. However, exposure of capsids to increasing temperatures or low pH led to its progressive accessibility without particle disassembly. Although unable to bind free virus or to block virus attachment to the cell, the anti-VP1u antibody was neutralizing, suggesting that the exposure of the epitope and the subsequent virus neutralization occur only after receptor attachment. The measurement of the VP1u-associated PLA(2) activity of B19 capsids revealed that this region is also internal but becomes exposed in heat- and in low-pH-treated particles. In sharp contrast to native virions, the VP1u of baculovirus-derived B19 capsids was readily accessible in the absence of any treatment. These results indicate that stretches of VP1u of native B19 capsids harboring neutralizing epitopes and essential functional motifs are not external to the capsid. However, a conformational change renders these regions accessible and triggers the PLA(2) potential of the virus. The results also emphasize major differences in the VP1u conformation between natural and recombinant particles.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17020940      PMCID: PMC1676260          DOI: 10.1128/JVI.01435-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface.

Authors:  S J Rosenfeld; K Yoshimoto; S Kajigaya; S Anderson; N S Young; A Field; P Warrener; G Bansal; M S Collett
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

2.  Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions.

Authors:  T Saikawa; S Anderson; M Momoeda; S Kajigaya; N S Young
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

3.  Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments.

Authors:  S F Cotmore; V C McKie; L J Anderson; C R Astell; P Tattersall
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

4.  Human parvovirus, the cause of erythema infectiosum (fifth disease)?

Authors:  M J Anderson; S E Jones; S P Fisher-Hoch; E Lewis; S M Hall; C L Bartlett; B J Cohen; P P Mortimer; M S Pereira
Journal:  Lancet       Date:  1983-06-18       Impact factor: 79.321

5.  Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions.

Authors:  S Kajigaya; H Fujii; A Field; S Anderson; S Rosenfeld; L J Anderson; T Shimada; N S Young
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

6.  Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus.

Authors:  Florian Sonntag; Svenja Bleker; Barbara Leuchs; Roger Fischer; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

7.  Immune response to B19 parvovirus and an antibody defect in persistent viral infection.

Authors:  G J Kurtzman; B J Cohen; A M Field; R Oseas; R M Blaese; N S Young
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

8.  Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures.

Authors:  K Ozawa; N Young
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

9.  Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins.

Authors:  C S Brown; J W Van Lent; J M Vlak; W J Spaan
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

10.  Human parvovirus-associated arthritis: a clinical and laboratory description.

Authors:  D M Reid; T M Reid; T Brown; J A Rennie; C J Eastmond
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

View more
  28 in total

1.  Selfness-nonselfness in designing an anti-B19 erythrovirus vaccine.

Authors:  Candida Fasano; Darja Kanduc
Journal:  Self Nonself       Date:  2011-04-01

2.  The structure and host entry of an invertebrate parvovirus.

Authors:  Geng Meng; Xinzheng Zhang; Pavel Plevka; Qian Yu; Peter Tijssen; Michael G Rossmann
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

Review 3.  Heterogeneous pathways of maternal-fetal transmission of human viruses (review).

Authors:  A Saleh Younes; Márta Csire; Beatrix Kapusinszky; Katalin Szomor; Mária Takács; György Berencsi
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

4.  Visualization of the externalized VP2 N termini of infectious human parvovirus B19.

Authors:  Bärbel Kaufmann; Paul R Chipman; Victor A Kostyuchenko; Susanne Modrow; Michael G Rossmann
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

5.  Globoside Is Dispensable for Parvovirus B19 Entry but Essential at a Postentry Step for Productive Infection.

Authors:  Jan Bieri; Carlos Ros
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

6.  Alterations in immunodominance of Streptococcus mutans AgI/II: lessons learned from immunomodulatory antibodies.

Authors:  Rebekah A Robinette; Kyle P Heim; Monika W Oli; Paula J Crowley; William P McArthur; L Jeannine Brady
Journal:  Vaccine       Date:  2013-11-16       Impact factor: 3.641

7.  Tyrosine cross-linking reveals interfacial dynamics in adeno-associated viral capsids during infection.

Authors:  Eric D Horowitz; M G Finn; Aravind Asokan
Journal:  ACS Chem Biol       Date:  2012-04-06       Impact factor: 5.100

8.  Characterization of the early steps of human parvovirus B19 infection.

Authors:  Silva Quattrocchi; Nico Ruprecht; Claudia Bönsch; Sven Bieli; Christoph Zürcher; Klaus Boller; Christoph Kempf; Carlos Ros
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

9.  Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity.

Authors:  Claudia Bönsch; Christoph Kempf; Carlos Ros
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

10.  Parvovirus B19 uptake is a highly selective process controlled by VP1u, a novel determinant of viral tropism.

Authors:  Remo Leisi; Nico Ruprecht; Christoph Kempf; Carlos Ros
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.